A Comparison of post-COVID vaccine myocarditis classification using the Brighton Collaboration criteria versus Centre for Disease Control criteria

Authors

  • Tessa R Marshall SAEFVIC, Murdoch Children’s Research Institute, Parkville
  • Silja Schrader SAEFVIC, Murdoch Children’s Research Institute, Parkville
  • Laura Voss SAEFVIC, Murdoch Children’s Research Institute, Parkville
  • Jim P Buttery SAEFVIC, Murdoch Children’s Research Institute, Parkville; Royal Children’s Hospital Melbourne, Parkville; Department of Paediatrics, University of Melbourne, Parkville; Centre for Health Analytics, Melbourne Children’s Campus, Parkville
  • Nigel W Crawford SAEFVIC, Murdoch Children’s Research Institute, Parkville; Royal Children’s Hospital Melbourne, Parkville; Department of Paediatrics, University of Melbourne, Parkville
  • Daryl R Cheng SAEFVIC, Murdoch Children’s Research Institute, Parkville; Royal Children’s Hospital Melbourne, Parkville; Department of Paediatrics, University of Melbourne, Parkville; Centre for Health Analytics, Melbourne Children’s Campus, Parkville

DOI:

https://doi.org/10.33321/cdi.2023.47.2

Keywords:

myocarditis, post-COVID vaccination reactions, criteria

Abstract

With its large dataset, our study provides a valuable assessment of the utility of different criteria for myocarditis post-COVID vaccination. Local guidelines may consider recommending the CDC case definition where CMR is available and the BC criteria where CMR is unavailable. The study highlights the ongoing importance of refining criteria for AEFI based on evolving data, outcomes and availability of diagnostic tools.

Downloads

Download data is not yet available.

References

Marshall M, Ferguson ID, Lewis P, Jaggi P, Gagliardo C, Collins JS et al. Symptomatic acute myocarditis in 7 adolescents after Pfizer-BioNTech COVID-19 vaccination. Pediatrics. 2021;148(3):e2021052478. doi: https://doi.org/10.1542/peds.2021-052478.

Cooper LT. Myocarditis: Causes and pathogenesis. [Webpage.] Alphen aan den Rijn: Wolters Kluwer Health, UpToDate; 9 May 2022. [Accessed on 14 May 2022.] Available from: https://www.uptodate.com/contents/myocarditis-causes-and-pathogenesis.

Sexson Tejtel SK, Munoz FM, Al-Ammouri I, Savorgnan F, Guggilla RK, Khuri-Bulos N et al. Myocarditis and pericarditis: case definition and guidelines for data collection, analysis, and presentation of immunization safety data. Vaccine. 2022;40(10):1499–511. doi: https://doi.org/10.1016/j.vaccine.2021.11.074.

Clothier HJ, Crawford NW, Russell M, Kelly H, Buttery JP. Evaluation of ‘SAEFVic’, a pharmacovigilance surveillance scheme for the spontaneous reporting of adverse events following immunisation in Victoria, Australia. Drug Saf. 2017;40(6):483–95. doi: https://doi.org/10.1007/s40264-017-0520-7.

Therapeutic Goods Administration (TGA). COVID-19 vaccine safety reports. [Internet.] Canberra: Australian Government Department of Health and Aged Care, TGA. [Accessed on 26 September 2022.] Available from: https://www.tga.gov.au/news/covid-19-vaccine-safety-reports.

Australian Government Department of Health and Aged Care. MBS Online: Medical Benefits Scheme. Cardiac magnetic resonance imaging (MRI) for myocarditis associated with mRNA COVID-19 vaccination. [Internet.] Canberra: Australian Government Department of Health and Aged Care; 1 April 2022. [Accessed on 15 July 2022.] Available from: http://www.mbsonline.gov.au/internet/mbsonline/publishing.nsf/Content/Factsheet-mRNA-Myo.

Downloads

Published

19/01/23

How to Cite

Marshall, Tessa R, Silja Schrader, Laura Voss, Jim P Buttery, Nigel W Crawford, and Daryl R Cheng. 2023. “A Comparison of Post-COVID Vaccine Myocarditis Classification Using the Brighton Collaboration Criteria Versus Centre for Disease Control Criteria”. Communicable Diseases Intelligence 47 (January). https://doi.org/10.33321/cdi.2023.47.2.

Issue

Vol. 47 (2023)

Section

Letter to the Editor

Categories

License

Copyright (c) 2023 Communicable Diseases Intelligence

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.